Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study

2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association

(2021) Kyu Yeon Hur et al.   Diabetes & Metabolism Journal

Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study

(2020) Yun Kyung Cho et al.   Diabetes Therapy

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Psychometric Analysis Regarding the Barriers to Providing Effective Insulin Treatment in Type 2 Diabetic Patients

(2020) Eu Jeong Ku et al.   Diabetes Therapy

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021

(2020)   DIABETES CARE

Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT

(2020) Muhammad Abdul-Ghani et al.   DIABETES CARE

Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study

(2019) Eu Jeong Ku et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

(2019) David R Matthews et al.   LANCET

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis

(2019) Lidan Yang et al.   Diabetes Therapy

Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus

(2019) Maria Mirabelli et al.   Journal of Diabetes Research

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETOLOGIA

Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control

(2018) Hyun Jeong Jeon et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice

(2018) Eu Jeong Ku et al.   DIABETES OBESITY & METABOLISM

Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling

(2018) Muthiah Vaduganathan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association

(2017) Seung-Hyun Ko et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials

(2016) Dandan Li et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis

(2016) F. Zaccardi et al.   DIABETES OBESITY & METABOLISM

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

(2016) Jason H Y Wu et al.   Lancet Diabetes & Endocrinology

Negative appraisals of insulin therapy are common among adults with Type 2 diabetes using insulin: Results from Diabetes MILES - Australia cross-sectional survey

(2015) E. Holmes-Truscott et al.   DIABETIC MEDICINE

Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review

(2015) C. J. Ng et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

SGLT2 Inhibitors May Predispose to Ketoacidosis

(2015) Simeon I. Taylor et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

(2015) Caroline Bonner et al.   NATURE MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

(2014) Kohei Kaku et al.   Cardiovascular Diabetology

Glucagon Regulates Hepatic Kisspeptin to Impair Insulin Secretion

(2014) Woo-Jin Song et al.   Cell Metabolism

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2014) André J. Scheen   DRUGS

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES CARE

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Correlates of Insulin Injection Omission

(2010) M. Peyrot et al.   DIABETES CARE

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS